Summary:
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 versus Vehicle in Subjects 2 years of age or older with Cutaneous Common Warts
Qualified Participants Must:
• Be greater than or equal to 2 years old
•
Have 1-6 verruca vulgaris measuring 3-10mm on hands/feet/limbs/trunk
•
Warts present for at least 4 weeks
Qualified Participants May Receive:
30 weeks of treatment study: 6 weeks of treatment + follow up
Gel vs. placebo 1:1
Non-destructive